These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 17095175

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H, Chavanet P.
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [Abstract] [Full Text] [Related]

  • 3. Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
    Etienne M, Croisier D, Charles PE, Lequeu C, Piroth L, Portier H, Drlica K, Chavanet P.
    J Infect Dis; 2004 Oct 15; 190(8):1472-5. PubMed ID: 15378440
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG, James J, Derkatch S, Laing N, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2006 Jul 15; 58(1):112-6. PubMed ID: 16644764
    [Abstract] [Full Text] [Related]

  • 5. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May 15; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep 15; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 8. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T.
    J Antimicrob Chemother; 2008 Jul 15; 62(1):98-104. PubMed ID: 18390884
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.
    De Vecchi E, Nicola L, Ossola F, Drago L.
    J Antimicrob Chemother; 2009 Apr 15; 63(4):721-7. PubMed ID: 19218275
    [Abstract] [Full Text] [Related]

  • 12. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
    Schurek KN, Adam HJ, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2006 Sep 15; 28(3):266-9. PubMed ID: 16904294
    [Abstract] [Full Text] [Related]

  • 13. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J, Hovde LB, Simonson D, Rotschafer JC.
    Diagn Microbiol Infect Dis; 2008 Feb 15; 60(2):155-61. PubMed ID: 17910998
    [Abstract] [Full Text] [Related]

  • 14. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
    Azoulay-Dupuis E, Bédos JP, Mohler J, Moine P, Cherbuliez C, Peytavin G, Fantin B, Köhler T.
    Antimicrob Agents Chemother; 2005 Mar 15; 49(3):1046-54. PubMed ID: 15728901
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro selection of fluoroquinolone resistance in Brucella melitensis.
    Ravanel N, Gestin B, Maurin M.
    Int J Antimicrob Agents; 2009 Jul 15; 34(1):76-81. PubMed ID: 19261448
    [Abstract] [Full Text] [Related]

  • 17. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage.
    Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T, CAPNETZ study group.
    Int J Med Microbiol; 2011 Jan 15; 301(1):53-7. PubMed ID: 20692869
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
    Lázaro FG, Rodríguez-Tarazona RE, García-Rodríguez JA, Muñoz-Bellido JL.
    Int J Antimicrob Agents; 2009 Sep 15; 34(3):252-4. PubMed ID: 19243922
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.